Upstream Bio Stock Forecast
NASDAQ: UPBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 3:40 PM ET
UPB analyst consensus
Consensus (7 analysts)
none
Avg. price target
$31.14+584.40%
- Strong buy 1
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Upstream Bio (2026-10-08), 5 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $31.14, with a high estimate of $75.00 and a low estimate of $9.00. The average target implies upside of 584.4% from the current price of $4.55.
The spread between the highest and lowest targets is 733.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for UPB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 4 | 57% |
| Hold | 2 | 29% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +97.80% |
| Average target | $31.14 | +584.40% |
| High target | $75.00 | +1548.35% |